AstraZeneca Annual Report and Form 20-F Information 2015金沙官网8331澳门


金沙官网app投注



2015 was an exceptional year for AstraZeneca, as we made significant progress in meeting both our near- and longer-term strategic goals.

Pascal Soriot, Chief Executive Officer




金沙官网app投注


All growth rates at CER.  



金沙官网app投注

金沙官网app投注

AstraZeneca is a global, science-led biopharmaceutical business with an on-market 文件夹 in our chosen therapy areas.




金沙官网app投注

We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices.

金沙官网8331澳门


金沙官网app投注

We have a strong global commercial presence, with strength in Emerging Markets.


金沙官网app投注

Our talented employees are committed to achieveing our Purpose in a sustainable way.



金沙官网app投注


金沙官网app投注


金沙官网app投注


All employee numbers are approximate as at 31 December 2015.



金沙官网app投注

Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.


金沙官网app投注

Gaithersburg, Maryland US
金沙官网app投注

Gothenburg, Sweden
金沙官网app投注




金沙官网app投注

Our disciplined capital allocation enables commitment to a progressive dividend.


Net cash shareholder distributions increased to $3,443 million
金沙官网8331澳门

金沙官网8331澳门

金沙官网8331澳门

金沙官网app投注

金沙官网8331澳门

The Board of Directors has sought to ensure that AstraZeneca's achievements in 2015 were underpinned by strong corporate governance.

Leif Johansson, Chairman